Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Partially aligned. The indication and core dosing frequency align with the label excerpt, but the weight-based 150 mg/300 mg dosing rule is not supported as stated (no ≥100 kg/<100 kg threshold in the provided label). Several safety/side-effect items and mechanism/symptom-improvement statements are unsupported or not verifiable from the provided excerpts.
Category Scores
Accurate Statements
Cosentyx is approved by the FDA to treat moderate to severe plaque psoriasis.
1.1
The recommended Cosentyx subcutaneous dosing in plaque psoriasis uses Weeks 0, 1, 2, 3, and 4 followed by every 4 weeks thereafter (including the phrasing of frequency).
2.3
Unsupported Statements
Cosentyx is a human monoclonal antibody that targets interleukin-17A (IL-17A).
Mechanism details (human monoclonal antibody; IL-17A target) are not present in the provided label excerpts.
Cosentyx reduces inflammation and slows down the growth of skin cells, leading to improved symptoms and quality of life for patients with psoriasis.
No such pharmacodynamic/clinical benefit rationale or 'slows growth of skin cells' statement is included in the provided label excerpts.
The recommended Cosentyx dosage is 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks for patients with a body weight of 100 kg or more.
The provided label excerpt for adults states 300 mg for the recommended adult dosage but does not include a ≥100 kg threshold.
The recommended Cosentyx dosage is 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks for patients with a body weight of less than 100 kg.
The provided label excerpt does not specify a <100 kg threshold. It includes an adult 'for some patients' 150 mg option, but not a weight cutoff of 100 kg, and pediatric thresholds differ.
A single psoriasis dose of Cosentyx typically ranges from 150 mg to 300 mg, depending on the patient's weight and the severity of their symptoms.
While 150 mg and 300 mg doses are referenced, the provided excerpt does not support 'typically ranges' tied to weight and severity phrasing.
The median dose of Cosentyx used in clinical trials was 300 mg.
No clinical trial median dose information is present in the provided label excerpts.
Potential side effects of Cosentyx include injection site reactions.
Adverse reaction examples such as injection site reactions are not listed in the provided adverse-reaction excerpt (only categories are referenced).
Potential side effects of Cosentyx include upper respiratory tract infections.
Infections are referenced generally as discussed elsewhere, but 'upper respiratory tract infections' is not specified in the provided excerpt.
Potential side effects of Cosentyx include nasopharyngitis.
Nasopharyngitis is not specified in the provided excerpts.
Potential side effects of Cosentyx include headache.
Headache is not specified in the provided excerpts.
Potential side effects of Cosentyx include fatigue.
Fatigue is not specified in the provided excerpts.
Contradictions
Low
AI Statement
The recommended Cosentyx dosage is 300 mg ... for patients with a body weight of 100 kg or more.
Label Reference
2.3
Low
AI Statement
The recommended Cosentyx dosage is 150 mg ... for patients with a body weight of less than 100 kg.
Label Reference
2.3
Important Omissions
Weight-based pediatric dosing thresholds (for pediatric patients 6 years and older: <50 kg = 75 mg; ≥50 kg = 150 mg).
Importance:
Moderate
Adult 'for some patients' 150 mg option is not clearly distinguished from the weight-threshold rule claimed (no adult ≥/</100 kg cutoff is shown in the provided excerpt).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The main potentially material mismatch is the asserted adult weight cutoff (100 kg) for 150 mg vs 300 mg, which could lead to dosing errors relative to the provided label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Dose selection by an unlabelled 100 kg adult threshold (≥100 kg vs <100 kg) and multiple unsupported adverse-effect/benefit/mechanism statements.
Suggested Improvement
Align dosing language to the provided excerpt: adults use 300 mg q4w after loading (with an optional 150 mg regimen 'for some patients' rather than a 100 kg cutoff); pediatric dosing uses <50 kg = 75 mg and ≥50 kg = 150 mg. Avoid listing specific adverse events (e.g., nasopharyngitis, headache, fatigue, injection site reactions) unless they are present in the provided label text.